The Top Cardiology Trials of 2018: ODYSSEY
Treatment with alirocumab, a PCSK9 inhibitor, reduced cardiovascular outcomes and all-cause deaths by 15% in patients with acute coronary syndrome (ACS) and higher-than-ideal atherogenic lipoprotein levels despite intensive or maximally tolerated statin therapy in the ODYSSEY trial.The ODYSSEY trial was a 3-year multicenter, randomized, double-blind, placebo-controlled trial involving almost 19,000 pat
Read the full story.
Create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies